Mimi C Tan1, Nabil Mansour1, Donna L White1,2, Amy Sisson3, Hashem B El-Serag1,2, Aaron P Thrift4,5. 1. Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA. 2. Houston VA HSR&D Center for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA. 3. The Texas Medical Center Library, Houston, TX, USA. 4. Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA. 5. Section of Epidemiology and Population Sciences, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
Abstract
BACKGROUND: The proportions of patients with oesophageal adenocarcinoma (OAC) diagnosed by Barrett's oesophagus surveillance or with pre-existing Barrett's oesophagus are unclear. AIM: To estimate the prevalence of prior and concurrent Barrett's oesophagus diagnosis among patients with OAC or oesophagogastric junction adenocarcinomas (OGJAC). METHODS: We searched PubMed and Embase to identify studies published 1966-1/8/2020 that examined the prevalence of prior (≥6 months) or concurrent Barrett's diagnosis (at cancer diagnosis) among OAC and OGJAC patients. Random effects models estimated overall and stratified pooled prevalence rates. RESULTS: A total of 69 studies, including 33 002 OAC patients (53 studies) and 2712 patients with OGJAC (28 studies) were included. The pooled prevalence of prior Barrett's oesophagus diagnosis in OAC was 11.8% (95% confidence interval [CI] 8.4%-15.6%). The prevalence of prior Barrett's oesophagus diagnosis was higher in single-centre resection studies (16.0%, 95% CI 8.7%-24.9%) than population-based cancer registry studies (8.4%, 95% CI 5.5%-11.9%). The prevalence of concurrent Barrett's oesophagus in OAC was 56.6% (95% CI 48.5%-64.6%). Studies with 100% early stage OAC had higher prevalence of concurrent Barrett's oesophagus (91.3%, 95% CI 82.4%-97.6%) than studies with <50% early OAC (39.7%, 95% CI 33.7%-45.9%). In OGJAC, the prevalence of prior and concurrent Barrett's oesophagus was 23.2% (95% CI 7.5%-44.0%) and 26.3% (95% CI 17.8%-35.7%), respectively. CONCLUSIONS: Most patients with OAC have Barrett's oesophagus. Our meta-analysis found ~12% of OAC patients had prior Barrett's diagnosis, but concurrent Barrett's oesophagus was found in ~57% at the time of OAC diagnosis. This represents a considerable missed opportunity for Barrett's oesophagus screening.
BACKGROUND: The proportions of patients with oesophageal adenocarcinoma (OAC) diagnosed by Barrett's oesophagus surveillance or with pre-existing Barrett's oesophagus are unclear. AIM: To estimate the prevalence of prior and concurrent Barrett's oesophagus diagnosis among patients with OAC or oesophagogastric junction adenocarcinomas (OGJAC). METHODS: We searched PubMed and Embase to identify studies published 1966-1/8/2020 that examined the prevalence of prior (≥6 months) or concurrent Barrett's diagnosis (at cancer diagnosis) among OAC and OGJAC patients. Random effects models estimated overall and stratified pooled prevalence rates. RESULTS: A total of 69 studies, including 33 002 OAC patients (53 studies) and 2712 patients with OGJAC (28 studies) were included. The pooled prevalence of prior Barrett's oesophagus diagnosis in OAC was 11.8% (95% confidence interval [CI] 8.4%-15.6%). The prevalence of prior Barrett's oesophagus diagnosis was higher in single-centre resection studies (16.0%, 95% CI 8.7%-24.9%) than population-based cancer registry studies (8.4%, 95% CI 5.5%-11.9%). The prevalence of concurrent Barrett's oesophagus in OAC was 56.6% (95% CI 48.5%-64.6%). Studies with 100% early stage OAC had higher prevalence of concurrent Barrett's oesophagus (91.3%, 95% CI 82.4%-97.6%) than studies with <50% early OAC (39.7%, 95% CI 33.7%-45.9%). In OGJAC, the prevalence of prior and concurrent Barrett's oesophagus was 23.2% (95% CI 7.5%-44.0%) and 26.3% (95% CI 17.8%-35.7%), respectively. CONCLUSIONS: Most patients with OAC have Barrett's oesophagus. Our meta-analysis found ~12% of OAC patients had prior Barrett's diagnosis, but concurrent Barrett's oesophagus was found in ~57% at the time of OAC diagnosis. This represents a considerable missed opportunity for Barrett's oesophagus screening.
Authors: Paulus G Schurr; Emre F Yekebas; Jussuf T Kaifi; Steffi Lasch; Tim Strate; Asad Kutup; Guel Cataldegirmen; Michael Bubenheim; Klaus Pantel; Jakob R Izbicki Journal: J Surg Oncol Date: 2006-09-15 Impact factor: 3.454
Authors: Douglas A Corley; Kunal Mehtani; Charles Quesenberry; Wei Zhao; Jolanda de Boer; Noel S Weiss Journal: Gastroenterology Date: 2013-05-11 Impact factor: 22.682
Authors: Nandan P Deshpande; Stephen M Riordan; Claire J Gorman; Shaun Nielsen; Tonia L Russell; Carolina Correa-Ospina; Bentotage S M Fernando; Shafagh A Waters; Natalia Castaño-Rodríguez; Si Ming Man; Nicodemus Tedla; Marc R Wilkins; Nadeem O Kaakoush Journal: Genome Med Date: 2021-08-19 Impact factor: 11.117
Authors: Joel H Rubenstein; Richard R Evans; Jennifer A Burns; Maria E Arasim; Ji Zhu; Akbar K Waljee Journal: Gastroenterology Date: 2021-12-20 Impact factor: 22.682
Authors: Ravy K Vajravelu; Jennifer M Kolb; Shivani U Thanawala; Frank I Scott; Samuel Han; Amit G Singal; Gary W Falk; David A Katzka; Sachin Wani Journal: Clin Gastroenterol Hepatol Date: 2021-02-05 Impact factor: 13.576
Authors: Julie A Webster; Alain Wuethrich; Karthik B Shanmugasundaram; Renee S Richards; Wioleta M Zelek; Alok K Shah; Louisa G Gordon; Bradley J Kendall; Gunter Hartel; B Paul Morgan; Matt Trau; Michelle M Hill Journal: Cancers (Basel) Date: 2021-06-08 Impact factor: 6.575
Authors: Ksenia S Maslyonkina; Alexandra K Konyukova; Darya Y Alexeeva; Mikhail Y Sinelnikov; Liudmila M Mikhaleva Journal: Cancer Med Date: 2021-12-06 Impact factor: 4.452